Biotech Bankruptcies: What to Expect in 2024 Following a Record Year?
March 20, 2024 Sarah Stevens, Ph.D.
In this Labiotech article, Azzur Group's President of Azzur Labs & Azzur Cleanrooms on Demand™, Sarah Stevens, provides insight into how the biotech industry is navigating through economic uncertainty and a funding drought, marked by a surge in bankruptcies extending into 2024. She emphasizes the necessity for the industry to adapt and explore innovative strategies to ensure resilience and long-term success.
“Scientifically, formulation and manufacturing process innovation is necessary to keep pace with cell and gene therapy opportunities. There are constraints related to fit-for-purpose, flexible manufacturing capacity.” - Sarah Stevens, President of Azzur Labs & Azzur Cleanrooms on Demand™ at Azzur Group
Gain additional insights from industry experts on innovative strategies, partnerships, and the trajectory toward recovery in the full Labiotech article linked below.
